Mabwell has passed an on-site Good Manufacturing Practice inspection conducted by Brazil’s National Health Surveillance Agency, ANVISA, covering the company’s 9MW0311 and 9MW0321 denosumab injections. The Chinese biopharmaceutical company said the inspection was completed through its wholly owned subsidiary T-mab and described it as its second GMP certification involving an authority participating in the Pharmaceutical Inspection Co-operation Scheme, following an earlier certification in Jordan.
The development removes an important manufacturing-quality hurdle from Mabwell’s effort to bring the two biosimilars into Brazil, but it should not be confused with marketing approval. Mabwell has already submitted marketing authorisation applications for its denosumab products in Brazil as part of filings across eight countries, meaning the regulatory review of the products themselves remains a separate step before commercialisation can begin.
That distinction makes the latest milestone more significant than a routine factory inspection, but less definitive than a product approval. For biosimilar manufacturers seeking international expansion, the commercial pathway depends not only on demonstrating product comparability, but also on convincing regulators that manufacturing processes, controls, quality systems and commercial production can consistently reproduce the product described in the registration dossier. ANVISA’s inspection therefore strengthens Mabwell’s execution position in Brazil without determining the ultimate outcome of its pending applications.
Mabwell also enters this stage with a local commercial structure already in place. In August 2024, the company signed a licensing and commercialisation agreement with Brazilian pharmaceutical manufacturer Cristália Produtos Químicos Farmacêuticos, under which Cristália is responsible for registration and commercialisation of the denosumab products in Brazil. That earlier deal means Mabwell’s Brazilian strategy is further advanced than simply identifying a potential future market after regulatory clearance.
Why does the ANVISA GMP inspection matter if Mabwell has not yet received Brazilian marketing approval?
GMP inspection and marketing authorisation address different components of regulatory risk. A product can have a convincing analytical and clinical biosimilarity package while still facing questions about whether its commercial manufacturing operation can reproducibly deliver material meeting defined quality standards. Conversely, a manufacturing site passing inspection does not establish that the regulator has accepted the entire evidence package supporting approval of a particular product.
For Mabwell, the ANVISA inspection matters because both 9MW0311 and 9MW0321 are biologics, where manufacturing consistency is particularly important. Changes in cell culture conditions, purification, formulation and other production variables can affect critical quality attributes, making process control part of the regulatory foundation rather than a secondary operational issue.
ANVISA has participated in PIC/S since January 1, 2021, following a multiyear assessment of the Brazilian regulator’s GMP inspection system. PIC/S is designed to promote common GMP standards, inspector training and confidence between participating regulatory authorities, giving successful inspections by member authorities broader credibility in an international manufacturing strategy. It remains a cooperative regulatory framework, however, rather than a mechanism through which a Brazilian inspection automatically produces marketing approval in other jurisdictions.
Mabwell has accordingly characterised the Brazilian result as its second PIC/S GMP certification. The more practical interpretation is that the company is accumulating evidence that its manufacturing quality system can withstand scrutiny from multiple overseas regulators, an increasingly important capability as it tries to convert China-developed biologics into products sold across emerging international markets.
How different are Mabwell’s 9MW0311 and 9MW0321 denosumab biosimilar programmes?
Although both products contain denosumab and target the RANKL pathway, they are being developed and commercialised against different reference-product franchises and at different doses.
9MW0311 is a 60 mg denosumab injection developed as a biosimilar to Prolia. China’s National Medical Products Administration approved the product, marketed there as MAILISHU, in March 2023 for postmenopausal women with osteoporosis at high risk of fracture. Mabwell subsequently secured marketing authorisation for 9MW0311 in Pakistan, where the product formed part of the company’s first overseas regulatory approval for its denosumab portfolio.
9MW0321 is the 120 mg programme developed as a biosimilar to Xgeva. It received Chinese marketing approval in March 2024 initially for adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgery is likely to cause severe morbidity. In May 2026, China’s National Medical Products Administration approved additional indications covering patients with bone metastases from solid tumours and patients with multiple myeloma, for delaying or reducing the risk of skeletal-related events.
Both 9MW0311 and 9MW0321 also received marketing authorisation from Pakistan’s Drug Regulatory Authority in 2025. That approval was commercially important for Mabwell because it demonstrated that the company could move the products beyond its domestic regulatory system and obtain its first overseas marketing authorisations.
The Brazilian filings therefore represent another test of whether Mabwell can replicate that progression in a substantially different regulatory environment and with an established local partner.
What does the Phase III evidence for 9MW0321 show about Mabwell’s biosimilar strategy?
The clinical evidence supporting 9MW0321 is more substantial than the latest manufacturing announcement alone might suggest. A randomized, double-blind Phase III equivalence study published in JAMA Oncology evaluated the programme, identified in the publication as MW032, against reference denosumab in patients with solid tumours and bone metastases.
The study randomized 708 patients at 46 centres in China, with 701 included in the evaluable population. Participants received either MW032 or reference denosumab every four weeks, with the primary endpoint assessing percentage change in urinary N-telopeptide to creatinine ratio from baseline to week 13. The reported difference fell within the prespecified equivalence margin, while secondary bone-turnover measures and the observed incidence of skeletal-related events were also similar between the groups.
The study provides useful support for the biosimilarity case, although its limitations remain relevant when interpreting the broader clinical package. The authors identified the absence of longer-term data on time to first skeletal-related event and overall survival as limitations, while the primary endpoint was a surrogate bone-turnover measure rather than a direct long-term patient outcome. The trial was also sponsored by Mabwell, with sponsor employees participating in aspects of the study and publication process, disclosures that should be considered when assessing the evidence alongside regulatory review.
For the Brazilian programme, however, the significance is not that the ANVISA inspection somehow validates those clinical findings. Rather, Mabwell is assembling the separate components required for international biosimilar commercialisation: comparative evidence, regulatory submissions, manufacturing compliance and local market infrastructure.
Why is Cristália important to Mabwell’s denosumab commercialisation strategy in Brazil?
Mabwell’s 2024 agreement with Cristália substantially changes the execution equation because the Chinese developer is not attempting to build a Brazilian commercial operation from scratch. Under the agreement disclosed by Mabwell, Cristália is responsible for registration and commercialisation of the denosumab products in Brazil.
That division of responsibilities gives Mabwell access to a domestic organisation familiar with regulatory procedures and commercial distribution while allowing Mabwell to retain responsibility for the underlying product and manufacturing platform. The structure resembles a broader strategy visible across the company’s denosumab expansion, where Mabwell has formed partnerships in markets including Pakistan, the Philippines, Malaysia, Vietnam and other emerging-market territories.
For biosimilars, such partnerships can be particularly important because approval is only the beginning of the adoption process. Local pricing, payer access, physician familiarity, distribution reliability and competitive tendering can influence how quickly an approved biosimilar gains meaningful utilisation. The existence of an experienced local partner reduces some infrastructure requirements, but it does not remove those market-access challenges.
The Brazilian opportunity will therefore depend on far more than the successful completion of one manufacturing inspection. A commercially relevant outcome requires completion of product review, approval of the appropriate indications, reliable supply and an effective launch strategy capable of competing in the local denosumab market.
Does PIC/S recognition give Mabwell a shortcut into other international denosumab markets?
Mabwell has presented the inspection as supporting access to a broader group of PIC/S markets, and there is a logical manufacturing rationale behind that argument. PIC/S seeks to harmonise GMP inspection standards and increase confidence among regulatory authorities, so a manufacturing system that repeatedly satisfies participating authorities may face less uncertainty than one entering international inspection for the first time.
That benefit should not be interpreted as passporting. Regulatory authorities retain responsibility for their own product approvals, dossier assessments and inspection decisions. A successful ANVISA inspection can strengthen the manufacturing record Mabwell presents internationally, but each registration programme can still involve jurisdiction-specific requirements and regulatory judgement.
This nuance matters because Mabwell says marketing applications for the two denosumab products have already been submitted in eight countries, including Brazil. The company is therefore moving from a predominantly China-focused biosimilar developer toward a multi-market commercialisation model, and manufacturing credibility becomes increasingly valuable as the number of jurisdictions expands.
What should the industry watch next in Mabwell’s Brazil denosumab registration process?
The next decisive development is not another manufacturing headline but the status of the Brazilian marketing authorisation applications. Mabwell has confirmed that Brazil is among eight countries where applications have been submitted, while Cristália has been positioned as the local registration and commercialisation partner. ANVISA’s GMP inspection removes one visible manufacturing issue from that pathway, but Mabwell has not announced Brazilian marketing approval for either 9MW0311 or 9MW0321.
Approval would shift the story rapidly from regulatory readiness toward launch execution. At that point, the relevant questions would include the exact authorised indications, pricing strategy, supply arrangements, competitive positioning and how Cristália intends to build uptake across Brazil’s public and private healthcare channels.
Until then, the August inspection is best understood as regulatory de-risking rather than commercial arrival. Mabwell now has two denosumab products already authorised in China and Pakistan, an established Brazilian partner, pending international registration applications and a manufacturing operation that has passed another overseas GMP inspection.
The commercial test is whether those individual pieces can now be converted into additional approvals and sustained international sales. Brazil is particularly important because a successful registration would demonstrate that Mabwell’s emerging-market biosimilar strategy can progress beyond initial overseas approvals into another major regulatory jurisdiction, while giving the company a stronger reference point for subsequent international expansion.
